ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
Key opinion leaders interviewed by GlobalData have anticipated the TRIUMPH-1 readout with considerable interest.
Therapy Area
EHA26: Epcoritamab improves PFS but not OS in R/R LBCL
ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Parabilis Medicines sets biotech record with $670m IPO
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
ASCO26: In vivo oncology approaches continue to show promise
